clinical trial · NCT07199452
A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)
Merck Sharp & Dohme LLC·phase1·completed·n = 18
HealthyMK-4646Rifabutin
brief summary
Researchers have designed a new study medicine called MK-4646 as a new way to treat human immunodeficiency virus (HIV). Rifabutin is a medication used to treat tuberculosis (TB). Researchers want to learn about MK-4646 when taken at the same time as Rifabutin. They want to: Measure a person's blood to find out if the amount of MK-4646 in the blood is the same when MK-4646 is taken alone or with Rifabutin Learn about the safety of MK-4646 when taken alone or with Rifabutin and if people tolerate it
started
Oct 28, 2025
primary completion
Dec 27, 2025
completion
Jan 7, 2026
last updated
Jan 29, 2026
official title
An Open-Label Clinical Study to Evaluate the Effects of Multiple Oral Doses of Rifabutin on the Single-Dose Pharmacokinetics of MK-4646 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol